Jazz Pharmaceuticals Plc (JAZZ)

179.60
1.80 1.00
NASDAQ : Health Technology
Prev Close 177.81
Open 177.11
Day Low/High 176.29 / 180.00
52 Wk Low/High 128.58 / 179.65
Volume 309.87K
Avg Volume 484.30K
Exchange NASDAQ
Shares Outstanding 60.00M
Market Cap 10.69B
EPS 8.10
P/E Ratio 24.40
Div & Yield N.A. (N.A)

Latest News

Jazz Pharmaceuticals Presents Long-Term Safety And Efficacy Data For Xyrem® (sodium Oxybate) In Pediatric Patients With Narcolepsy With Cataplexy

Jazz Pharmaceuticals Presents Long-Term Safety And Efficacy Data For Xyrem® (sodium Oxybate) In Pediatric Patients With Narcolepsy With Cataplexy

DUBLIN, June 3, 2018 /PRNewswire/ --  Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Xyrem® (sodium oxybate) oral solution, CIII, demonstrated long-term efficacy for up to one year in reducing cataplexy and excessive daytime sleepiness (EDS)...

New Survey Highlights Lack Of Awareness Of Neurologic Effects Related To Excessive Sleepiness In Patients With Obstructive Sleep Apnea

Survey findings show that while pulmonologists, neurologists and psychiatrists are aware of the negative effects of Excessive Sleepiness (ES) on patients' quality of life, few are familiar with emerging research linking the condition to brain alterations [1],[2]

Why Thousands Will Attend ASH Hematology Conference in Atlanta This Weekend

Why Thousands Will Attend ASH Hematology Conference in Atlanta This Weekend

The FDA approved 11 different hematological treatments this year after approving 11 in the previous two years combined.

Acorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers

Acorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers

The firm received a "refusal to file letter" from the FDA regarding the new drug application for Inbrija, a potential treatment for Parkinson's disease.

Jazz Pharmaceuticals And ImmunoGen, Inc. Announce A Strategic Collaboration And Option Agreement To Develop And Commercialize Antibody-Drug Conjugate Products

Jazz Pharmaceuticals And ImmunoGen, Inc. Announce A Strategic Collaboration And Option Agreement To Develop And Commercialize Antibody-Drug Conjugate Products

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and ImmunoGen, Inc. (Nasdaq: IMGN) today announced that the companies have entered into a collaboration and option agreement granting Jazz Pharmaceuticals exclusive, worldwide rights...

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Biotech Movers: Jazz Shares Lower Amid Notes Offering

The Dublin firm announced an offering of $500 million of exchangeable senior notes due 2024.

Medivation Founder Takes Helm at Axovant, Shares Spike

Medivation Founder Takes Helm at Axovant, Shares Spike

David Hung will become Axovant's CEO after completing the $14 billion sale of Medivation to Pfizer.

Trevena, Synergy Lead Biotech Movers

Trevena, Synergy Lead Biotech Movers

Positive phase three data was a boon for Trevena, but Synergy's "Poop Troop" put pressure on its stock.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACSF, CAA, JAZZ, LFL, MTH, SUM, WYNN Downgrades: REV, TROW, WAGE Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix

Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix

ChemoCentryx, Jazz Pharmaceuticals, Ionis Pharmaceuticals and Zogenix were among the biotech stock movers in premarket trading Friday.

How Investors Can Play the Trump Card: Cramer's 'Mad Money' Recap (Monday 1/23/17)

How Investors Can Play the Trump Card: Cramer's 'Mad Money' Recap (Monday 1/23/17)

Jim Cramer looks for domestic stocks he thinks will benefit from lower taxes and deregulation in the Trump era.

Fitbit Is Out, Xilinx Is In: 'Mad Money' Lightning Round

Fitbit Is Out, Xilinx Is In: 'Mad Money' Lightning Round

Jim Cramer says the future doesn't look healthy for Fitbit, but he's bullish on Xilinx and T-Mobile.

Jazz Pharma, CoLucid Spike Premarket, Plus Other Biotech Movers

Jazz Pharma, CoLucid Spike Premarket, Plus Other Biotech Movers

CoLucid Pharmaceuticals saw shares boost 32% ahead of the market open Wednesday.

The Best Biopharma CEOs of 2016 Are...

The Best Biopharma CEOs of 2016 Are...

The negative investor sentiment for health care stocks in 2016 presented a particularly challenging environment to accomplish anything well. Each of these CEOs met the challenge and succeeded.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CSWC, FNV, INTT, SCHL, VSAT Downgrades: AE, ASH, CNTY, CVV, HCOM, JAZZ, JLL, KND, MAC, MGNX, NS, OLED, OLP, SCSC, SEAS, TGH, XNCR Initiations: ABTX Read on to get TheStreet Quant Ratings' detailed report:

Jazz Pharmaceuticals Stock Retreats as Q3 Falls Short

Jazz Pharmaceuticals Stock Retreats as Q3 Falls Short

Jazz Pharmaceuticals's third-quarter results missed analysts' projections.

Trader's Daily Notebook: For a Decline, It Sure Was Smooth

But we could see more volatility in the market.

Pharma Has History of Price Gouging, Mylan Should Be No Surprise

Pharma Has History of Price Gouging, Mylan Should Be No Surprise

While the public seized on Mylan's price increases for EpiPens, the story of a common drug industry practice - increasing prices ahead of generics entering the market - got lost.

TheStreet Quant Rating: B (Buy)